Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 857 genomic deals announced since 2016 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties.
Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of genomic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter Highlights
The initial chapters of this report provide an orientation of genomic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in genomic dealmaking since 2016.
Chapter 3 provides an overview of the leading genomic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomic technology type in focus.
Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse genomic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Genomic Collaboration and Licensing Deals includes:
- Trends in genomic dealmaking in the biopharma industry
- Directory of genomic deal records covering pharmaceutical and biotechnology
- The leading genomic deals by value
- Most active genomic licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in genomic dealmaking
2.1. Introduction
2.2. Genomic deals over the years
2.3. Most active genomic dealmakers
2.4. Genomic deals by deal type
2.5. Genomic deals by therapy area
2.6. Genomic deals by industry sector
2.7. Deal terms for genomic deals
2.7.1 Genomic deals headline values
2.7.2 Genomic deal upfront payments
2.7.3 Genomic deal milestone payments
2.7.4 Genomic royalty rates
Chapter 3 - Leading genomic deals
3.1. Introduction
3.2. Top genomic deals by value
Chapter 4 - Most active genomic dealmakers
4.1. Introduction
4.2. Most active genomic dealmakers
4.3. Most active genomic deals company profiles
Chapter 5 - Genomic contracts dealmaking directory
5.1. Introduction
5.2. Genomic contracts dealmaking directory
Chapter 6 - Genomic dealmaking by technology type
Deal directory
Deal directory - Genomic deals by company A-Z
Deal directory - Genomic deals by deal type
Deal directory - Genomic deals by therapy area
For more information about this report visit https://www.researchandmarkets.com/r/qk0q7f
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
